期刊文献+

安肺益肾方对COPD大鼠血清IL-2、IFN-γ、IgA、IgG及脾淋巴细胞增殖的影响 被引量:3

下载PDF
导出
摘要 目的:探讨安肺益肾方对慢性阻塞性肺疾病模型大鼠血清IL-2、IFN-γ、IgA、IgG及脾淋巴细胞增殖的作用。方法:健康Wistar大鼠72只,采用半随机单盲法分为安肺益肾方大、中、小剂量组、氨茶碱组、模型组、正常对照组,每组12只,除正常对照组外,其余各组大鼠采用熏香烟加气管注入内毒素法建立慢性阻塞性肺疾病模型。安肺益肾方大、中、小剂量组分别给予生药2.4、1.2、0.6g/kg,氨茶碱组予氨茶碱15mg/kg。模型组和正常组灌胃0.5%羧甲基纤维素溶液,连续给药4周。用ELISA法检测血清IL-2、IFN-γ、IgA、IgG含量;取大鼠脾脏,用MTT比色法检测脾淋巴细胞增殖情况。结果:安肺益肾方能降低慢性阻塞性肺疾病模型大鼠血清IFN-γ表达(P<0.01);提高血清IL-2、IgA、IgG水平(P<0.05);增强脾T淋巴细胞增殖(P<0.001)。结论:安肺益肾方可调节慢性阻塞性肺疾病模型大鼠的免疫功能。
出处 《中国中医药科技》 CAS 2013年第4期357-358,360,共3页 Chinese Journal of Traditional Medical Science and Technology
  • 相关文献

参考文献11

  • 1曹静,陈红雨.慢性阻塞性肺疾病中医药研究概况[J].中国中医药科技,2008,15(5):397-398. 被引量:15
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8232
  • 3吴建军,姜良铎,鲁香凤,张晓梅,张伟,庞宝森.安肺益肾方对慢性阻塞性肺疾病模型大鼠肺功能的影响[J].中医杂志,2012,53(17):1492-1494. 被引量:7
  • 4庞宝森,李远红,张洪玉.慢性阻塞性肺疾病动物模型的研究进展[J].心肺血管病杂志,2005,24(1):45-46. 被引量:12
  • 5Nikota JK, St;impfli MR. Cigarette smoke - induced inflammation and respiratory host defense: Insights from animal models. Pulm Pharmacol Ther,2012,25(4) :257.
  • 6Paats MS, Bergen IM, Hoogsteden HC, et al. Systemic CD4+ and CDs+ T - cell cytokine profiles correlate with GOLD stage in stable COPD. Eur Respir J, 2012, 40(2) :330.
  • 7Bengoechea JA. Secretory IgA and COPD: a new kid on the block? Am J Respir Grit Care Mod, 2011, 184(3) :285.
  • 8Strugnell RA, Wijburg OL. The role of secretory antibodies in in- fection immunity. Nat Rev Mierebiol, 2010, 8(9) :656.
  • 9Takahashi T, Muro S, Tanabe N, et al. Relationship between pe- riodontitis -related antibody and frequent exacerbations in chronic obstructive pulmonary disease. Phos One, 2012, 7 (7) : e40570.
  • 10ChenC, ShenY, Ni CJ, et al. Imbalance of circulating T - lym- phocyte subpopulation in COPD and its relationship with CAT per- formance. J Lab Anal, 2012, 26(2) :109.

二级参考文献30

共引文献8251

同被引文献26

  • 1徐卫华,沈华浩.肺泡巨噬细胞合成转化生长因子β1在慢性阻塞性肺疾病气道重塑中的作用[J].中华结核和呼吸杂志,2005,28(1):57-58. 被引量:7
  • 2Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, managemen!, and prevention of chronic obstructive pulmonary disease. Updated 2011.www. goldcopd.com(accessed 21 Sep 2011 ).
  • 3McDonald CF, Khor Y. Advances in chronic obstructive pul- monary disease [ J ]. Intern Med J, 2013,43 (8) : 854-862.
  • 4Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis,Management and Prevention of COPD. Updated December 2007.www.goldcopd. com. (accessed 4 Sep 2008).
  • 5Pellegrino R, Viegi G, Bmsaseo V, et al. Interpretative strate- gies for lung function tests [J ]. Eur Respir J, 2005,26 (4) : 948- 968.
  • 6何欣,霍丽.COPD支气管舒张试验后肺容量和呼气流量反应的差异[D].辽宁:大连医科大学,2011.
  • 7Heldin CH.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.J Neuroimmune Pharmacol,2013,DO1 10.1007/s11481-01309484-2.
  • 8Mukherjee S,Duan F,Kolb MR,et al.Platelet derived growth factor-evoked Ca2+ wave and matrix gene expression through phospholipase C in human pulmonary fibroblast.Int J Biochem Cell Biol,2013,45(7):1516.
  • 9Mortaz E,Givi ME,Da Silva CA,et al.A relation between TGF-β and mast cell tryptase in experimental emphysema models.Biochim Biophys Acta,2012,1822 (7):1154.
  • 10Andrianifahanana M,Wilkes MC,Gupta SK,et al.Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.FASEB J,2013,doi:10.1096/fj.12-224907.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部